Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (s-KL) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. For further details, the full press release can be accessed at https://ibn.fm/x2pHA.
This patent grant is significant because it strengthens Greenland Mines' position in the gene therapy field, particularly for age-related cognitive decline and neurodegenerative conditions. The s-KL variant has shown potential in preclinical studies to enhance cognitive function and protect against neuronal damage. By securing intellectual property in Canada, the company now has patent protection in key global markets, which could facilitate future partnerships, licensing deals, and commercialization efforts. The advancement of KLTO-101 and KLTO-202 into manufacturing stages indicates progress toward clinical trials, bringing potential treatments closer to patients suffering from devastating diseases like ALS and Alzheimer's.
The company operates two divisions: mining and biotech. Its biotech division focuses on developing Klotho-based therapies, with KLTO-202 targeting ALS as a primary indication. The mining division is involved in the exploration and development of the Skaergaard Project in southeast Greenland and the Sarfartoq rare earths project. This dual structure provides diversification, but the recent patent news highlights the potential value in its biotech pipeline. Investors and stakeholders can follow the latest updates on the company's newsroom at https://ibn.fm/GRML.
The implications of this announcement extend beyond Greenland Mines. Successful development of Klotho gene therapies could revolutionize treatment for neurodegenerative diseases, which currently have limited options. The patent also underscores the growing importance of gene therapy in addressing complex disorders. However, as with all forward-looking statements, the company cautions that actual results may differ due to risks and uncertainties detailed in its SEC filings. The full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
